



1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Morishita et al.

Art Unit: 1635

Application No. 09/869,475

CERTIFICATE OF MAILING

Filed: June 28, 2001

For: GENE THERAPY FOR DIABETIC
ISCHEMIC DISEASE

Examiner: Brian A. Whitehead

Date: October 18, 2002

I hereby certify that this paper and the documents referred to as
being attached or enclosed herewith are being deposited with the
United States Postal Service on October 18, 2002, as First Class
Mail in an envelope addressed to: COMMISSIONER FOR
PATENTS, WASHINGTON D.C. 20231.

Susan Alpert Siegel, Ph.D.
Agent for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

RECEIVED

OCT 29 2002

TECH CENTER 1600/2900

Enclosed for filing in the application referenced above are the following:

- ☐ Information Disclosure Statement
 - ☒ Form 1449 and references cited thereon
 - ☒ IDS Fee of \$180.00
- ☐ A check in the amount of \$180.00 to cover the above-listed fee
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☐ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



SA:jam 10/18/02 6235-59221 147891

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Morishita et al.

Art Unit: 1635

Application No. 09/869,475

CERTIFICATE OF MAILING


Filed: June 28, 2001

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 18, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

For: GENE THERAPY FOR DIABETIC
ISCHEMIC DISEASE

Examiner: Brian A. Whiteman

Date: October 18, 2002


Susan Alpert Siegel, Ph.D.
Agent for Applicant

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Listed on the accompanying form PTO-1449 and enclosed herewith are two document.

EP 1 136 083 A1 is the European national phase patent application that corresponds to WO 01/26694. Although WO 01/26694 is in Japanese, EP 1 136 083 A1 is in English, and they are believed to be the same text. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application. The filing of this Information Disclosure Statement should not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in § 1.56(b).

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement in compliance with 1.97(c).

COPY


Please charge any additional fees which may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550.

A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446